Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report - Scorecard - MDSpire
Advertisement
Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report
Clinical Scorecard: SSTR2-Targeted Therapy Combined with 177Lu-DOTATATE and Octreotide for Treatment-Resistant Meningioma: A Case Study
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Patients with treatment-resistant meningioma, particularly those with NF2 mutations.
Care Setting
Key Highlights
Meningiomas are the most common primary intracranial tumors in adults.
Combination therapy with 177Lu-DOTATATE and octreotide shows promise for refractory cases.
The patient demonstrated stable disease with a reduction in tumor size post-treatment, but treatment was discontinued due to non-treatment related causes.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Potential for toxicity from systemic therapies; monitor for adverse effects, particularly from 177Lu-DOTATATE and octreotide.
Patient & Prescribing Data
Received 177Lu-DOTATATE and octreotide; treatment was discontinued due to non-treatment related causes, specifically due to the patient's death.
Clinical Best Practices
Consider combination therapies for refractory meningiomas.
Monitor for disease progression and treatment response using standardized criteria.
Consider genetic testing for NF2 mutations in patients with meningioma.
by Carlen A. Yuen, Mahbod Jafarvand, David O. Kamson, Eleanor Chu, Jennifer E. Soun, William H. Yong, Frank P. Hsu, Hansen Bow, Michelle Zheng, Shyam M. Srinivas
